[TMA]-Pharmacology Watch: Tamoxifen, SSRIs, and Breast Cancer Recurrence
Aug31
Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch
Archive August 2009
[PCR]-Reducing Polypharmacy: Prudent Prescribing in Primary Care
Aug31
Reducing Polypharmacy: Prudent Prescribing in Primary CareAuthors:Dean A. Bricker, MD, Assistant Professor of Medicine, Wright State University, Boonshoft School of Medicine, Dayton, OH; and Anne H. Metzger, PharmD, Assistant Professor of Pharmacy Practice, University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, OH.Peer Reviewer:Cynthia Sheppard Solomon, BPharm, RPh, FASCP, President, Sheppard-Solomon Biomedical [...]
[CTU]-New emergency contraception options are here, but how are you to use them?
Aug31
New emergency contraception options are here, but how are you to use them?FDA approves Plan B One-Step and Next ChoiceGetting ready to advise your next patient about the importance of emergency contraception (EC)? Be prepared to discuss two new emergency contraceptive products, just approved by the Food and Drug Administration (FDA):
?Plan B One-Step (levonorgestrel tablet, [...]
[CRC]-Pharmacology Watch: Tamoxifen, SSRIs, and Breast Cancer Recurrence
Aug31
Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch
[IDA]-Pharmacology Watch: Tamoxifen, SSRIs, and Breast Cancer Recurrence
Aug31
Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch
[SHW]-Fiscal Fitness: How States Cope: New Mexico Medicaid has some difficult choices to make for FY 2010
Aug31
Fiscal Fitness: How States CopeNew Mexico Medicaid has some difficult choices to make for FY 2010A long list of proposed cost- containment possibilities for New Mexico’s Medicaid program never happened, due to funding the state received from the American Recovery and Reinvestment Act (ARRA) of 2009. Other than tightening up its managed care contracts, [...]
Research and Markets: Emerging Opportunities in Controlled-Release Generic Drugs: New Report Identifies 30 Controlled-Release Drugs Valued at US$15 Billion
Aug31
DUBLIN(BUSINESS WIRE) Research and Markets has announced the addition of the "Emerging Opportunities in Controlled-Release Generic Drugs" report to their offering. This [...]
